Osteoporosis is defined as a systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration leading to increased fracture risk. Osteoporosis incidence increases with age in both post-menopausal women and aging men. Among other important contributing factors to bone fragility observed in osteoporosis, that also affect the elderly population, are metabolic disturbances observed in obesity and Type 2 Diabetes (T2D). These metabolic complications are associated with impaired bone homeostasis and a higher fracture risk. Expansion of the Bone Marrow Adipose Tissue (BMAT), at the expense of decreased bone formation, is thought to be one of the key pathogenic mechanisms underlying osteoporosis and bone fragility in obesity and T2D. Our review provides a summary of mechanisms behind increased Bone Marrow Adiposity (BMA) during aging and highlights the pre-clinical and clinical studies connecting obesity and T2D, to BMA and bone fragility in aging osteoporotic women and men.

Department of Cellular and Molecular Medicine University of Copenhagen Copenhagen Denmark

Department of Molecular Endocrinology KMEB University of Southern Denmark and Odense University Hospital Odense Denmark

Laboratory of Molecular Physiology of Bone Institute of Physiology of the Czech Academy of Sciences Prague Czechia

Zobrazit více v PubMed

Armas LA, Recker RR. Pathophysiology of osteoporosis: New mechanistic insights. Endocrinol Metab Clin North Am (2012) 41:475–86. doi: 10.1016/j.ecl.2012.04.006 PubMed DOI

Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 17:1726–33. doi: 10.1007/s00198-006-0172-4 PubMed DOI

Liu J, Curtis EM, Cooper C, Harvey NC. State of the art in osteoporosis risk assessment and treatment. J Endocrinol Invest (2019) 42:1149–64. doi: 10.1007/s40618-019-01041-6 PubMed DOI PMC

Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int (1994) 4:368–81. doi: 10.1007/BF01622200 PubMed DOI

Kanis JA, Melton LJ, 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res (1994) 9:1137–41. doi: 10.1002/jbmr.5650090802 PubMed DOI

Kassem M, Marie PJ. Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell (2011) 10:191–7. doi: 10.1111/j.1474-9726.2011.00669.x PubMed DOI

Marie PJ, Kassem M. Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets. Eur J Endocrinol (2011) 165:1–10. doi: 10.1530/EJE-11-0132 PubMed DOI

Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res (2007) 22:724–9. doi: 10.1359/jbmr.070207 PubMed DOI

Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, et al. . Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res (1999) 14:2150–8. doi: 10.1359/jbmr.1999.14.12.2150 PubMed DOI

Locatelli V, Bianchi VE. Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis. Int J Endocrinol (2014) 2014:235060. doi: 10.1155/2014/235060 PubMed DOI PMC

Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell (2013) 153:1194–217. doi: 10.1016/j.cell.2013.05.039 PubMed DOI PMC

Seeman E. Pathogenesis of bone fragility in women and men. Lancet (2002) 359:1841–50. doi: 10.1016/S0140-6736(02)08706-8 PubMed DOI

Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am (2005) 34:1015–30. doi: 10.1016/j.ecl.2005.07.009 PubMed DOI

Rauch A, Haakonsson AK, Madsen JGS, Larsen M, Forss I, Madsen MR, et al. . Osteogenesis depends on commissioning of a network of stem cell transcription factors that act as repressors of adipogenesis. Nat Genet (2019) 51:716–27. doi: 10.1038/s41588-019-0359-1 PubMed DOI

Rozman C, Feliu E, Berga L, Reverter JC, Climent C, Ferran MJ. Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes: a stereological study. Exp Hematol (1989) 17:34–7. PubMed

Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, et al. . Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood (2015) 125:249–60. doi: 10.1182/blood-2014-04-572255 PubMed DOI PMC

Han L, Zhang Y, Wan S, Wei Q, Shang W, Huang G, et al. . Loss of chemerin triggers bone remodeling in vivo and in vitro. Mol Metab (2021) 53:101322. doi: 10.1016/j.molmet.2021.101322 PubMed DOI PMC

Herrmann M. Marrow Fat-Secreted Factors as Biomarkers for Osteoporosis. Curr Osteoporos Rep (2019) 17:429–37. doi: 10.1007/s11914-019-00550-w PubMed DOI PMC

Jafari A, Qanie D, Andersen TL, Zhang Y, Chen L, Postert B, et al. . Legumain Regulates Differentiation Fate of Human Bone Marrow Stromal Cells and Is Altered in Postmenopausal Osteoporosis. Stem Cell Rep (2017) 8:373–86. doi: 10.1016/j.stemcr.2017.01.003 PubMed DOI PMC

de Magalhães JP, Passos JF. Stress, cell senescence and organismal ageing. Mech Ageing Dev (2018) 170:2–9. doi: 10.1016/j.mad.2017.07.001 PubMed DOI

Roger L, Tomas F, Gire V. Mechanisms and regulation of cellular senescence. Int J Mol Sci (2021) 22. doi: 10.3390/ijms222313173 PubMed DOI PMC

Zhu X, Chen Z, Shen W, Huang G, Sedivy JM, Wang H, et al. . Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention. Signal Transduct Target Ther (2021) 6:245. doi: 10.1038/s41392-021-00646-9 PubMed DOI PMC

Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med (2015) 21:1424–35. doi: 10.1038/nm.4000 PubMed DOI PMC

Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol (2010) 5:99–118. doi: 10.1146/annurev-pathol-121808-102144 PubMed DOI PMC

Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. . Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PloS Biol (2008) 6:2853–68. doi: 10.1371/journal.pbio.0060301 PubMed DOI PMC

Swanson EC, Manning B, Zhang H, Lawrence JB. Higher-order unfolding of satellite heterochromatin is a consistent and early event in cell senescence. J Cell Biol (2013) 203:929–42. doi: 10.1083/jcb.201306073 PubMed DOI PMC

Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest (2013) 123:966–72. doi: 10.1172/JCI64098 PubMed DOI PMC

von Zglinicki T, Saretzki G, Ladhoff J, d’Adda di Fagagna F, Jackson SP. Human cell senescence as a DNA damage response. Mech Ageing Dev (2005) 126:111–7. doi: 10.1016/j.mad.2004.09.034 PubMed DOI

Ziegler DV, Wiley CD, Velarde MC. Mitochondrial effectors of cellular senescence: beyond the free radical theory of aging. Aging Cell (2015) 14:1–7. doi: 10.1111/acel.12287 PubMed DOI PMC

Kajkenova O, Lecka-Czernik B, Gubrij I, Hauser SP, Takahashi K, Parfitt AM, et al. . Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res (1997) 12:1772–9. doi: 10.1359/jbmr.1997.12.11.1772 PubMed DOI

Farr JN, Fraser DG, Wang H, Jaehn K, Ogrodnik MB, Weivoda MM, et al. . Identification of Senescent Cells in the Bone Microenvironment. J Bone Miner Res (2016) 31:1920–9. doi: 10.1002/jbmr.2892 PubMed DOI PMC

Farr JN, Xu M, Weivoda MM, Monroe DG, Fraser DG, Onken JL, et al. . Targeting cellular senescence prevents age-related bone loss in mice. Nat Med (2017) 23:1072–9. doi: 10.1038/nm.4385 PubMed DOI PMC

Atashi F, Modarressi A, Pepper MS. The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: A review. Stem Cells Dev (2015) 24:1150–63. doi: 10.1089/scd.2014.0484 PubMed DOI PMC

Ali D, Chen L, Kowal JM, Okla M, Manikandan M, AlShehri M, et al. . Resveratrol inhibits adipocyte differentiation and cellular senescence of human bone marrow stromal stem cells. Bone (2020) 133:115252. doi: 10.1016/j.bone.2020.115252 PubMed DOI

Chandra A, Lagnado AB, Farr JN, Schleusner M, Monroe DG, Saul D, et al. . Bone Marrow Adiposity in Models of Radiation- and Aging-Related Bone Loss Is Dependent on Cellular Senescence. J Bone Miner Res (2022) 37:997–1011. doi: 10.1002/jbmr.4537 PubMed DOI PMC

Dimri GP, Itahana K, Acosta M, Campisi J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol (2000) 20:273–85. doi: 10.1128/MCB.20.1.273-285.2000 PubMed DOI PMC

Zhou X, Sen I, Lin XX, Riedel CG. Regulation of age-related decline by transcription factors and their crosstalk with the epigenome. Curr Genomics (2018) 19:464–82. doi: 10.2174/1389202919666180503125850 PubMed DOI PMC

Li H, Liu P, Xu S, Li Y, Dekker JD, Li B, et al. . FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging. J Clin Invest (2017) 127:1241–53. doi: 10.1172/JCI89511 PubMed DOI PMC

Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell (2004) 3:379–89. doi: 10.1111/j.1474-9728.2004.00127.x PubMed DOI PMC

Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. A role of miR-27 in the regulation of adipogenesis. FEBS J (2009) 276:2348–58. doi: 10.1111/j.1742-4658.2009.06967.x PubMed DOI PMC

Peterson CL, Cote J. Cellular machineries for chromosomal DNA repair. Genes Dev (2004) 18:602–16. doi: 10.1101/gad.1182704 PubMed DOI

Masamoto Y, Arai S, Sato T, Kubota N, Takamoto I, Kadowaki T, et al. . Adiponectin Enhances Quiescence Exit of Murine Hematopoietic Stem Cells and Hematopoietic Recovery Through mTORC1 Potentiation. Stem Cells (2017) 35:1835–48. doi: 10.1002/stem.2640 PubMed DOI

Zhou BO, Yu H, Yue R, Zhao Z, Rios JJ, Naveiras O, et al. . Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF. Nat Cell Biol (2017) 19:891–903. doi: 10.1038/ncb3570 PubMed DOI PMC

Bolan PJ, Arentsen L, Sueblinvong T, Zhang Y, Moeller S, Carter JS, et al. . Water-fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients. J Magn Reson Imaging (2013) 38:1578–84. doi: 10.1002/jmri.24071 PubMed DOI PMC

Kim HN, Chang J, Shao L, Han L, Iyer S, Manolagas SC, et al. . DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age. Aging Cell (2017) 16:693–703. doi: 10.1111/acel.12597 PubMed DOI PMC

Chandra A, Wang L, Young T, Zhong L, Tseng WJ, Levine MA, et al. . Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis. FASEB J (2018) 32:52–62. doi: 10.1096/fj.201700375R PubMed DOI PMC

Chandra A, Lin T, Young T, Tong W, Ma X, Tseng WJ, et al. . Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms. J Bone Miner Res (2017) 32:360–72. doi: 10.1002/jbmr.2996 PubMed DOI PMC

Marie PJ, Kassem M. Extrinsic mechanisms involved in age-related defective bone formation. J Clin Endocrinol Metab (2011) 96:600–9. doi: 10.1210/jc.2010-2113 PubMed DOI

Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev (2004) 25:389–425. doi: 10.1210/er.2003-0003 PubMed DOI

Khosla S, Melton LJ, 3rd, Riggs BL. Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab (2002) 87:1443–50. doi: 10.1210/jcem.87.4.8417 PubMed DOI

Forbes AP, Albright F. His concept of postmenopausal osteoporosis and what came of it. Clin Orthop Relat Res (1991), 128–41. PubMed

Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet (1976) 1:1038–41. doi: 10.1016/s0140-6736(76)92217-0 PubMed DOI

Abdallah BM, Bay-Jensen AC, Srinivasan B, Tabassi NC, Garnero P, Delaisse JM, et al. . Estrogen inhibits Dlk1/FA1 production: A potential mechanism for estrogen effects on bone turnover. J Bone Miner Res (2011) 26:2548–51. doi: 10.1002/jbmr.444 PubMed DOI PMC

Abdallah BM, Ditzel N, Mahmood A, Isa A, Traustadottir GA, Schilling AF, et al. . DLK1 is a novel regulator of bone mass that mediates estrogen deficiency-induced bone loss in mice. J Bone Miner Res (2011) 26:1457–71. doi: 10.1002/jbmr.346 PubMed DOI

Jacobsen BK, Bonaa KH. The reproducibility of dietary data from a self-administered questionnaire. The Tromso Study. Int J Epidemiol (1990) 19:349–53. doi: 10.1093/ije/19.2.349 PubMed DOI

Almeida M, Martin-Millan M, Ambrogini E, Bradsher R, 3rd, Han L, Chen XD, et al. . Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. J Bone Miner Res (2010) 25:769–81. doi: 10.1359/jbmr.091017 PubMed DOI PMC

Kousteni S, Almeida M, Han L, Bellido T, Jilka RL, Manolagas SC. Induction of osteoblast differentiation by selective activation of kinase-mediated actions of the estrogen receptor. Mol Cell Biol (2007) 27:1516–30. doi: 10.1128/MCB.01550-06 PubMed DOI PMC

Wiren KM, Semirale AA, Zhang XW, Woo A, Tommasini SM, Price C, et al. . Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton. Bone (2008) 43:440–51. doi: 10.1016/j.bone.2008.04.026 PubMed DOI PMC

Prakasam G, Yeh JK, Chen MM, Castro-Magana M, Liang CT, Aloia JF. Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats. Bone (1999) 24:491–7. doi: 10.1016/s8756-3282(99)00018-6 PubMed DOI

Orwoll ES. Androgens as anabolic agents for bone. Trends Endocrinol Metab (1996) 7:77–84. doi: 10.1016/1043-2760(96)00024-0 PubMed DOI

Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med (2008) 358:1474–82. doi: 10.1056/NEJMcp0707217 PubMed DOI

Marie PJ, de Vernejoul MC, Connes D, Hott M. Decreased DNA synthesis by cultured osteoblastic cells in eugonadal osteoporotic men with defective bone formation. J Clin Invest (1991) 88:1167–72. doi: 10.1172/JCI115418 PubMed DOI PMC

Khosla S, Melton LJ, 3rd, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab (1998) 83:2266–74. doi: 10.1210/jcem.83.7.4924 PubMed DOI

Falahati-Nini A, Riggs BL, Atkinson EJ, O’Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 106:1553–60. doi: 10.1172/JCI10942 PubMed DOI PMC

Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2008) 29:155–92. doi: 10.1210/er.2007-0014 PubMed DOI PMC

Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis–the second decade. Endocrinology (1998) 139:2659–61. doi: 10.1210/endo.139.6.6087 PubMed DOI

Zallone A. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci (2006) 1068:173–9. doi: 10.1196/annals.1346.019 PubMed DOI

Ha H, Kwak HB, Lee SW, Jin HM, Kim HM, Kim HH, et al. . Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res (2004) 301:119–27. doi: 10.1016/j.yexcr.2004.07.035 PubMed DOI

Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Partington GA, et al. . A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest (2003) 112:915–23. doi: 10.1172/JCI18859 PubMed DOI PMC

Tencerova M, Figeac F, Ditzel N, Taipaleenmaki H, Nielsen TK, Kassem M. High-fat diet-induced obesity promotes expansion of bone marrow adipose tissue and impairs skeletal stem cell functions in mice. J Bone Miner Res (2018) 33:1154–65. doi: 10.1002/jbmr.3408 PubMed DOI

Tencerova M, Frost M, Figeac F, Nielsen TK, Ali D, Lauterlein JL, et al. . Obesity-associated hypermetabolism and accelerated senescence of bone marrow stromal stem cells suggest a potential mechanism for bone fragility. Cell Rep (2019) 27:2050–2062.e6. doi: 10.1016/j.celrep.2019.04.066 PubMed DOI

Marie PJ, Sabbagh A, de Vernejoul MC, Lomri A. Osteocalcin and deoxyribonucleic acid synthesis in vitro and histomorphometric indices of bone formation in postmenopausal osteoporosis. J Clin Endocrinol Metab (1989) 69:272–9. doi: 10.1210/jcem-69-2-272 PubMed DOI

Modrowski D, Miravet L, Feuga M, Marie PJ. Increased proliferation of osteoblast precursor cells in estrogen-deficient rats. Am J Physiol (1993) 264:E190–6. doi: 10.1152/ajpendo.1993.264.2.E190 PubMed DOI

Griffith JF, Yeung DK, Ma HT, Leung JC, Kwok TC, Leung PC. Bone marrow fat content in the elderly: A reversal of sex difference seen in younger subjects. J Magn Reson Imaging (2012) 36:225–30. doi: 10.1002/jmri.23619 PubMed DOI

Woods GN, Ewing SK, Sigurdsson S, Kado DM, Eiriksdottir G, Gudnason V, et al. . Greater bone marrow adiposity predicts bone loss in older women. J Bone Miner Res (2020) 35:326–32. doi: 10.1002/jbmr.3895 PubMed DOI

Griffith JF, Yeung DK, Antonio GE, Lee FK, Hong AW, Wong SY, et al. . Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: Ddynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology (2005) 236:945–51. doi: 10.1148/radiol.2363041425 PubMed DOI

Rothman MS, Iwamoto SJ. Bone Health in the Transgender Population. Clin Rev Bone Mineral Metab (2019) 17:77–85. doi: 10.1007/s12018-019-09261-3 PubMed DOI PMC

Bretherton I, Ghasem-Zadeh A, Leemaqz SY, Seeman E, Wang X, McFarlane T, et al. . Bone microarchitecture in transgender adults: A cross-sectional study. J Bone Miner Res (2022) 37:643–8. doi: 10.1002/jbmr.4497 PubMed DOI PMC

Nasomyont N, Meisman AR, Ecklund K, Vajapeyam S, Cecil KM, Tkach JA, et al. . Changes in bone marrow adipose tissue in transgender and gender non-conforming youth undergoing pubertal suppression: A pilot study. J Clin Densitometry (2022). doi: 10.1016/j.jocd.2022.06.006 PubMed DOI PMC

Khosla S, Samakkarnthai P, Monroe DG, Farr JN. Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus. Nat Rev Endocrinol (2021) 17:685–97. doi: 10.1038/s41574-021-00555-5 PubMed DOI PMC

Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL, et al. . Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol (2017) 13:208–19. doi: 10.1038/nrendo.2016.153 PubMed DOI

Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, et al. . An atlas of genetic influences on osteoporosis in humans and mice. Nat Genet (2019) 51:258–66. doi: 10.1038/s41588-018-0302-x PubMed DOI PMC

Riggs BL, Wahner HW, Seeman E, Offord KP, Dunn WL, Mazess RB, et al. . Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest (1982) 70:716–23. doi: 10.1172/jci110667 PubMed DOI PMC

Lecka-Czernik B, Stechschulte LA, Czernik PJ, Dowling AR. High bone mass in adult mice with diet-induced obesity results from a combination of initial increase in bone mass followed by attenuation in bone formation; implications for high bone mass and decreased bone quality in obesity. Mol Cell Endocrinol (2015) 410:35–41. doi: 10.1016/j.mce.2015.01.001 PubMed DOI

Halade GV, Rahman MM, Williams PJ, Fernandes G. High fat diet-induced animal model of age-associated obesity and osteoporosis. J Nutr Biochem (2010) 21:1162–9. doi: 10.1016/j.jnutbio.2009.10.002 PubMed DOI PMC

Doucette CR, Horowitz MC, Berry R, MacDougald OA, Anunciado-Koza R, Koza RA, et al. . A high fat diet increases bone marrow adipose tissue (mat) but does not alter trabecular or cortical bone mass in c57bl/6j mice. J Cell Physiol (2015) 230:2032–7. doi: 10.1002/jcp.24954 PubMed DOI PMC

Scheller EL, Khoury B, Moller KL, Wee NK, Khandaker S, Kozloff KM, et al. . Changes in skeletal integrity and marrow adiposity during high-fat diet and after weight loss. Front Endocrinol (Lausanne) (2016) 7:102. doi: 10.3389/fendo.2016.00102 PubMed DOI PMC

Bredella MA, Gill CM, Keating LK, Torriani M, Anderson EJ, Punyanitya M, et al. . Assessment of abdominal fat compartments using DXA in premenopausal women from anorexia nervosa to morbid obesity. Obes (Silver Spring) (2013) 21:2458–64. doi: 10.1002/oby.20424 PubMed DOI PMC

Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, et al. . Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. Obes (Silver Spring) (2011) 19:49–53. doi: 10.1038/oby.2010.106 PubMed DOI PMC

Yu EW, Greenblatt L, Eajazi A, Torriani M, Bredella MA. Marrow adipose tissue composition in adults with morbid obesity. Bone (2017) 97:38–42. doi: 10.1016/j.bone.2016.12.018 PubMed DOI PMC

Bilha SC, Leustean L, Preda C, Branisteanu DD, Mihalache L, Ungureanu MC. Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus. BMC Endocr Disord (2021) 21:156. doi: 10.1186/s12902-021-00815-5 PubMed DOI PMC

Figeac F, Tencerova M, Ali D, Andersen TL, Appadoo DRC, Kerckhofs G, et al. . Impaired Bone Fracture Healing in Type 2 Diabetes Is Caused by Defective Functions of Skeletal Progenitor Cells. Stem Cells (2022) 40:149–64. doi: 10.1093/stmcls/sxab011 PubMed DOI

Fintini D, Cianfarani S, Cofini M, Andreoletti A, Ubertini GM, Cappa M, et al. . The Bones of Children With Obesity. Front Endocrinol (Lausanne) (2020) 11:200. doi: 10.3389/fendo.2020.00200 PubMed DOI PMC

Walsh JS, Vilaca T. Obesity, Type 2 Diabetes and Bone in Adults. Calcif Tissue Int (2017) 100:528–35. doi: 10.1007/s00223-016-0229-0 PubMed DOI PMC

Tonks KT, White CP, Center JR, Samocha-Bonet D, Greenfield JR. Bone Turnover Is Suppressed in Insulin Resistance, Independent of Adiposity. J Clin Endocrinol Metab (2017) 102:1112–21. doi: 10.1210/jc.2016-3282 PubMed DOI

Migliaccio S, Greco EA, Fornari R, Donini LM, Lenzi A. Is obesity in women protective against osteoporosis? Diabetes Metab Syndr Obes (2011) 4:273–82. doi: 10.2147/DMSO.S11920 PubMed DOI PMC

Kin K, Kushida K, Yamazaki K, Okamoto S, Inoue T. Bone mineral density of the spine in normal Japanese subjects using dual-energy X-ray absorptiometry: effect of obesity and menopausal status. Calcif Tissue Int (1991) 49:101–6. doi: 10.1007/BF02565129 PubMed DOI

Ribot C, Tremollieres F, Pouilles JM, Bonneu M, Germain F, Louvet JP. Obesity and postmenopausal bone loss: The influence of obesity on vertebral density and bone turnover in postmenopausal women. Bone (1987) 8:327–31. doi: 10.1016/8756-3282(87)90062-7 PubMed DOI

Jang M, Kim H, Lea S, Oh S, Kim JS, Oh B. Effect of duration of diabetes on bone mineral density: A population study on East Asian males. BMC Endocr Disord (2018) 18:61. doi: 10.1186/s12902-018-0290-y PubMed DOI PMC

Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. . Risk of fracture in women with type 2 diabetes: The Women’s Health Initiative Observational Study. J Clin Endocrinol Metab (2006) 91:3404–10. doi: 10.1210/jc.2006-0614 PubMed DOI

Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, et al. . Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA (2011) 305:2184–92. doi: 10.1001/jama.2011.715 PubMed DOI PMC

Farr JN, Drake MT, Amin S, Melton LJ, 3rd, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res (2014) 29:787–95. doi: 10.1002/jbmr.2106 PubMed DOI PMC

Cohen A, Dempster DW, Recker RR, Lappe JM, Zhou H, Zwahlen A, et al. . Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: A transiliac bone biopsy study. J Clin Endocrinol Metab (2013) 98:2562–72. doi: 10.1210/jc.2013-1047 PubMed DOI PMC

Carnevale V, Romagnoli E, D’Erasmo L, D’Erasmo E. Bone damage in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis (2014) 24:1151–7. doi: 10.1016/j.numecd.2014.06.013 PubMed DOI

Lee RH, Sloane R, Pieper C, Lyles KW, Adler RA, Van Houtven C, et al. . Glycemic control and insulin treatment alter fracture risk in older men with type 2 diabetes mellitus. J Bone Miner Res (2019) 34:2045–51. doi: 10.1002/jbmr.3826 PubMed DOI PMC

Vestergaard P. Diabetes and bone fracture: risk factors for old and young. Diabetologia (2014) 57:2007–8. doi: 10.1007/s00125-014-3338-1 PubMed DOI

Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol (2007) 166:495–505. doi: 10.1093/aje/kwm106 PubMed DOI

Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, et al. . Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab (2001) 86:32–8. doi: 10.1210/jcem.86.1.7139 PubMed DOI

Sheu Y, Amati F, Schwartz AV, Danielson ME, Li X, Boudreau R, et al. . Vertebral bone marrow fat, bone mineral density and diabetes: The Osteoporotic Fractures in Men (MrOS) study. Bone (2017) 97:299–305. doi: 10.1016/j.bone.2017.02.001 PubMed DOI PMC

Fazeli PK, Bredella MA, Pachon-Peña G, Zhao W, Zhang X, Faje AT, et al. . The dynamics of human bone marrow adipose tissue in response to feeding and fasting. JCI Insight (2021) 6. doi: 10.1172/jci.insight.138636 PubMed DOI PMC

Kim TY, Schwartz AV, Li X, Xu K, Black DM, Petrenko DM, et al. . Bone marrow fat changes after gastric bypass surgery are associated with loss of bone mass. J Bone Miner Res (2017) 32:2239–47. doi: 10.1002/jbmr.3212 PubMed DOI PMC

Vogt LJ, Steveling A, Meffert PJ, Kromrey ML, Kessler R, Hosten N, et al. . Magnetic resonance imaging of changes in abdominal compartments in obese diabetics during a low-calorie weight-loss program. PloS One (2016) 11:e0153595. doi: 10.1371/journal.pone.0153595 PubMed DOI PMC

Kerckhofs G, Durand M, Vangoitsenhoven R, Marin C, van der Schueren B, Carmeliet G, et al. . Changes in bone macro- and microstructure in diabetic obese mice revealed by high resolution microfocus X-ray computed tomography. Sci Rep (2016) 6:35517. doi: 10.1038/srep35517 PubMed DOI PMC

Tanaka H, Yamashita T, Yoneda M, Takagi S, Miura T. Characteristics of bone strength and metabolism in type 2 diabetic model Tsumura, Suzuki, Obese Diabetes mice. Bone Rep (2018) 9:74–83. doi: 10.1016/j.bonr.2018.07.004 PubMed DOI PMC

Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest (2003) 112:1785–8. doi: 10.1172/JCI20514 PubMed DOI PMC

Mundy GR. Osteoporosis and inflammation. Nutr Rev (2007) 65:S147–51. doi: 10.1111/j.1753-4887.2007.tb00353.x PubMed DOI

Wright E, Jr., Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: The role of fasting and postprandial glycaemia. Int J Clin Pract (2006) 60:308–14. doi: 10.1111/j.1368-5031.2006.00825.x PubMed DOI PMC

Dos Santos JM, Tewari S, Mendes RH. The role of oxidative stress in the development of diabetes mellitus and its complications. J Diabetes Res (2019) 2019:4189813. doi: 10.1155/2019/4189813 PubMed DOI PMC

Yue R, Zhou BO, Shimada IS, Zhao Z, Morrison SJ. Leptin receptor promotes adipogenesis and reduces osteogenesis by regulating mesenchymal stromal cells in adult bone marrow. Cell Stem Cell (2016) 18:782–96. doi: 10.1016/j.stem.2016.02.015 PubMed DOI

Droge W. Oxidative aging and insulin receptor signaling. J Gerontol A Biol Sci Med Sci (2005) 60:1378–85. doi: 10.1093/gerona/60.11.1378 PubMed DOI

Devlin MJ, Van Vliet M, Motyl K, Karim L, Brooks DJ, Louis L, et al. . Early-onset type 2 diabetes impairs skeletal acquisition in the male TALLYHO/JngJ mouse. Endocrinology (2014) 155:3806–16. doi: 10.1210/en.2014-1041 PubMed DOI PMC

Ambrosi TH, Scialdone A, Graja A, Gohlke S, Jank AM, Bocian C, et al. . Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. Cell Stem Cell (2017) 20:771–784.e6. doi: 10.1016/j.stem.2017.02.009 PubMed DOI PMC

Boskey AL, Imbert L. Bone quality changes associated with aging and disease: a review. Ann N Y Acad Sci (2017) 1410:93–106. doi: 10.1111/nyas.13572 PubMed DOI PMC

Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature (2009) 460:259–63. PubMed PMC

Fantuzzi G, tissue A. adipokines, and inflammation. J Allergy Clin Immunol (2005) 115:911–9. doi: 10.1016/j.jaci.2005.02.023 PubMed DOI

Barbour KE, Zmuda JM, Boudreau R, Strotmeyer ES, Horwitz MJ, Evans RW, et al. . The effects of adiponectin and leptin on changes in bone mineral density. Osteoporos Int (2012) 23:1699–710. doi: 10.1007/s00198-011-1768-x PubMed DOI PMC

Basurto L, Galvan R, Cordova N, Saucedo R, Vargas C, Campos S, et al. . Adiponectin is associated with low bone mineral density in elderly men. Eur J Endocrinol (2009) 160:289–93. doi: 10.1530/EJE-08-0569 PubMed DOI

O’Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem (1999) 274:19301–8. doi: 10.1074/jbc.274.27.19301 PubMed DOI

Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone (2003) 32:1–7. doi: 10.1016/s8756-3282(02)00915-8 PubMed DOI

Li Y, Lu L, Xie Y, Chen X, Tian L, Liang Y, et al. . Interleukin-6 Knockout Inhibits Senescence of Bone Mesenchymal Stem Cells in High-Fat Diet-Induced Bone Loss. Front Endocrinol (Lausanne) (2020) 11:622950. doi: 10.3389/fendo.2020.622950 PubMed DOI PMC

Aaron N, Costa S, Rosen CJ, Qiang L. The Implications of Bone Marrow Adipose Tissue on Inflammaging. Front Endocrinol (Lausanne) (2022) 13:853765. doi: 10.3389/fendo.2022.853765 PubMed DOI PMC

Kozakowski J, Gietka-Czernel M, Leszczynska D, Majos A. Obesity in menopause - our negligence or an unfortunate inevitability? Prz Menopauzalny (2017) 16:61–5. doi: 10.5114/pm.2017.68594 PubMed DOI PMC

Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology (2001) 2:165–71. doi: 10.1023/a:1011513223894 PubMed DOI

Li G, Xu Z, Fan J, Yuan W, Zhang L, Hou L, et al. . To assess differential features of marrow adiposity between postmenopausal women with osteoarthritis and osteoporosis using water/fat MRI. Menopause (2017) 24:105–11. doi: 10.1097/GME.0000000000000732 PubMed DOI

Milisic L, Vegar-Zubovic S, Valjevac A. Bone marrow adiposity is inversely associated with bone mineral density in postmenopausal females. Med Glas (Zenica) (2020) 17:15–21. doi: 10.17392/1053-20 PubMed DOI

Sekiya I, Larson BL, Vuoristo JT, Cui JG, Prockop DJ. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). J Bone Miner Res (2004) 19:256–64. doi: 10.1359/JBMR.0301220 PubMed DOI

Nehlin JO, Jafari A, Tencerova M, Kassem M. Aging and lineage allocation changes of bone marrow skeletal (stromal) stem cells. Bone (2019) 123:265–73. doi: 10.1016/j.bone.2019.03.041 PubMed DOI

Salamat MR, Salamat AH, Janghorbani M. Association between obesity and bone mineral density by gender and menopausal status. Endocrinol Metab (Seoul) (2016) 31:547–58. doi: 10.3803/EnM.2016.31.4.547 PubMed DOI PMC

Silva HG, Mendonca LM, Conceicao FL, Zahar SE, Farias ML. Influence of obesity on bone density in postmenopausal women. Arq Bras Endocrinol Metabol (2007) 51:943–9. doi: 10.1590/s0004-27302007000600008 PubMed DOI

Bonjour JP. Dietary protein: An essential nutrient for bone health. J Am Coll Nutr (2005) 24:526S–36S. doi: 10.1080/07315724.2005.10719501 PubMed DOI

Kveiborg M, Rattan SI, Clark BF, Eriksen EF, Kassem M. Treatment with 1,25-dihydroxyvitamin D3 reduces impairment of human osteoblast functions during cellular aging in culture. J Cell Physiol (2001) 186:298–306. doi: 10.1002/1097-4652(200002)186:2<298::AID-JCP1030>3.0.CO;2-H PubMed DOI

Fretz JA, Zella LA, Kim S, Shevde NK, Pike JW. 1,25-Dihydroxyvitamin D3 regulates the expression of low-density lipoprotein receptor-related protein 5 via deoxyribonucleic acid sequence elements located downstream of the start site of transcription. Mol Endocrinol (2006) 20:2215–30. doi: 10.1210/me.2006-0102 PubMed DOI

van Driel M, van Leeuwen JP. Vitamin D endocrine system and osteoblasts. Bonekey Rep (2014) 3:493. doi: 10.1038/bonekey.2013.227 PubMed DOI PMC

Nakaoka K, Yamada A, Noda S, Goseki-Sone M. Influence of dietary vitamin D deficiency on bone strength, body composition, and muscle in ovariectomized rats fed a high-fat diet. Nutrition (2019) 60:87–93. doi: 10.1016/j.nut.2018.09.001 PubMed DOI

Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev (2001) 22:477–501. doi: 10.1210/edrv.22.4.0437 PubMed DOI

Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: Evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab (2007) 92:1415–23. doi: 10.1210/jc.2006-1404 PubMed DOI

Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, et al. . Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int (2002) 13:257–64. doi: 10.1007/s001980200023 PubMed DOI

Sahota O, Mundey MK, San P, Godber IM, Lawson N, Hosking DJ. The relationship between vitamin D and parathyroid hormone: Calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone (2004) 35:312–9. doi: 10.1016/j.bone.2004.02.003 PubMed DOI

Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. Lancet (2007) 370:657–66. doi: 10.1016/S0140-6736(07)61342-7 PubMed DOI

Ding J, Nagai K, Woo JT. Insulin-dependent adipogenesis in stromal ST2 cells derived from murine bone marrow. Biosci Biotechnol Biochem (2003) 67:314–21. doi: 10.1271/bbb.67.314 PubMed DOI

Kong J, Li YC. Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. Am J Physiol Endocrinol Metab (2006) 290:E916–24. doi: 10.1152/ajpendo.00410.2005 PubMed DOI

Whitfield GK, Hsieh JC, Nakajima S, MacDonald PN, Thompson PD, Jurutka PW, et al. . A highly conserved region in the hormone-binding domain of the human vitamin D receptor contains residues vital for heterodimerization with retinoid X receptor and for transcriptional activation. Mol Endocrinol (1995) 9:1166–79. doi: 10.1210/mend.9.9.7491109 PubMed DOI

Cianferotti L, Demay MB. VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells. J Cell Biochem (2007) 101:80–8. doi: 10.1002/jcb.21151 PubMed DOI

Duque G, Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res (2007) 22:1603–11. doi: 10.1359/jbmr.070701 PubMed DOI

Kelly KA, Gimble JM. 1,25-Dihydroxy vitamin D3 inhibits adipocyte differentiation and gene expression in murine bone marrow stromal cell clones and primary cultures. Endocrinology (1998) 139:2622–8. doi: 10.1210/endo.139.5.5970 PubMed DOI

Meehan M, Penckofer S. The role of vitamin d in the aging adult. J Aging Gerontol (2014) 2:60–71. doi: 10.12974/2309-6128.2014.02.02.1 PubMed DOI PMC

Ameri P, Giusti A, Boschetti M, Bovio M, Teti C, Leoncini G, et al. . Vitamin D increases circulating IGF1 in adults: Potential implication for the treatment of GH deficiency. Eur J Endocrinol (2013) 169:767–72. doi: 10.1530/EJE-13-0510 PubMed DOI

Gomez JM. The role of insulin-like growth factor I components in the regulation of vitamin D. Curr Pharm Biotechnol (2006) 7:125–32. doi: 10.2174/138920106776597621 PubMed DOI

Sadie-Van Gijsen H, Crowther NJ, Hough FS, Ferris WF. The interrelationship between bone and fat: From cellular see-saw to endocrine reciprocity. Cell Mol Life Sci (2013) 70:2331–49. doi: 10.1007/s00018-012-1211-2 PubMed DOI PMC

Baxter-Jones AD, Kontulainen SA, Faulkner RA, Bailey DA. A longitudinal study of the relationship of physical activity to bone mineral accrual from adolescence to young adulthood. Bone (2008) 43:1101–7. doi: 10.1016/j.bone.2008.07.245 PubMed DOI

Carter MI, Hinton PS. Physical activity and bone health. Mo Med (2014) 111:59–64. PubMed PMC

Styner M, Pagnotti GM, McGrath C, Wu X, Sen B, Uzer G, et al. . Exercise decreases marrow adipose tissue through ss-oxidation in obese running mice. J Bone Miner Res (2017) 32:1692–702. doi: 10.1002/jbmr.3159 PubMed DOI PMC

Pagnotti GM, Styner M. Exercise Regulation of Marrow Adipose Tissue. Front Endocrinol (Lausanne) (2016) 7:94. doi: 10.3389/fendo.2016.00094 PubMed DOI PMC

Belavy DL, Miller CT, Owen PJ, Rantalainen T, Connell D, Hahne AJ, et al. . Exercise may impact on lumbar vertebrae marrow adipose tissue: Randomised controlled trial. Bone (2022) 157:116338. doi: 10.1016/j.bone.2022.116338 PubMed DOI

Maddalozzo GF, Turner RT, Edwards CH, Howe KS, Widrick JJ, Rosen CJ, et al. . Alcohol alters whole body composition, inhibits bone formation, and increases bone marrow adiposity in rats. Osteoporos Int (2009) 20:1529–38. doi: 10.1007/s00198-009-0836-y PubMed DOI

Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpas MD. Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology (2011) 152:457–67. doi: 10.1210/en.2010-1098 PubMed DOI PMC

Dombrowski S, Kostev K, Jacob L. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data. Osteoporos Int (2017) 28:2421–8. doi: 10.1007/s00198-017-4051-y PubMed DOI

Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: A meta-analysis of randomized clinical trials. Diabetes Care (2011) 34:2474–6. doi: 10.2337/dc11-1099 PubMed DOI PMC

Sedlinsky C, Molinuevo MS, Cortizo AM, Tolosa MJ, Felice JI, Sbaraglini ML, et al. . Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats. Eur J Pharmacol (2011) 668:477–85. doi: 10.1016/j.ejphar.2011.07.033 PubMed DOI

Melton LJ, 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: Update of a population-based study. J Bone Miner Res (2008) 23:1334–42. doi: 10.1359/jbmr.080323 PubMed DOI PMC

Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. . Rosiglitazone-associated fractures in type 2 diabetes: An Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 31:845–51. doi: 10.2337/dc07-2270 PubMed DOI

Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, et al. . Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab (2010) 95:134–42. doi: 10.1210/jc.2009-0572 PubMed DOI

Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia (2005) 48:1292–9. doi: 10.1007/s00125-005-1786-3 PubMed DOI

Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F, et al. . Bone fractures and hypoglycemic treatment in type 2 diabetic patients: A case-control study. Diabetes Care (2008) 31:199–203. doi: 10.2337/dc07-1736 PubMed DOI

Stechschulte LA, Czernik PJ, Rotter ZC, Tausif FN, Corzo CA, Marciano DP, et al. . PPARG post-translational modifications regulate bone formation and bone resorption. EBioMedicine (2016) 10:174–84. doi: 10.1016/j.ebiom.2016.06.040 PubMed DOI PMC

Fukunaga T, Zou W, Rohatgi N, Colca JR, Teitelbaum SL, thiazolidinedione Ani-s. which minimally activates PPARgamma, does not cause bone loss. J Bone Miner Res (2015) 30:481–8. doi: 10.1002/jbmr.2364 PubMed DOI PMC

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, et al. . Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. J Hepatol (2020) 72:613–26. doi: 10.1016/j.jhep.2019.10.023 PubMed DOI

Lin Q, Huang YM, Xiao BX, Ren GF. Effects of resveratrol on bone mineral density in ovarectomized rats. Int J BioMed Sci (2005) 1:76–81. PubMed PMC

Yang X, Jiang T, Wang Y, Guo L. The role and mechanism of sirt1 in resveratrol-regulated osteoblast autophagy in osteoporosis rats. Sci Rep (2019) 9:18424. doi: 10.1038/s41598-019-44766-3 PubMed DOI PMC

Rios H, Koushik SV, Wang H, Wang J, Zhou HM, Lindsley A, et al. . periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol.Cell Biol (2005) 25:11131–44. PubMed PMC

Suen PK, Qin L. Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review. J Orthop Translat (2016) 4:1–13. doi: 10.1016/j.jot.2015.08.004 PubMed DOI PMC

Yee CS, Xie L, Hatsell S, Hum N, Murugesh D, Economides AN, et al. . Sclerostin antibody treatment improves fracture outcomes in a Type I diabetic mouse model. Bone (2016) 82:122–34. doi: 10.1016/j.bone.2015.04.048 PubMed DOI PMC

McDonald MM, Morse A, Mikulec K, Peacock L, Yu N, Baldock PA, et al. . Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res (2012) 30:1541–8. doi: 10.1002/jor.22109 PubMed DOI

Suen PK, He YX, Chow DH, Huang L, Li C, Ke HZ, et al. . Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats. J Orthop Res (2014) 32:997–1005. doi: 10.1002/jor.22636 PubMed DOI

Hamann C, Rauner M, Hohna Y, Bernhardt R, Mettelsiefen J, Goettsch C, et al. . Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res (2013) 28:627–38. doi: 10.1002/jbmr.1803 PubMed DOI

McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res (2014) 29:935–43. doi: 10.1002/jbmr.2092 PubMed DOI

Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, et al. . A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res (2015) 30:216–24. doi: 10.1002/jbmr.2351 PubMed DOI

Recknor CP, Recker RR, Benson CT, Robins DA, Chiang AY, Alam J, et al. . The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density. J Bone Miner Res (2015) 30:1717–25. doi: 10.1002/jbmr.2489 PubMed DOI

Rauner M, Taipaleenmaki H, Tsourdi E, Winter EM. Osteoporosis treatment with anti-sclerostin antibodies-mechanisms of action and clinical application. J Clin Med (2021) 10. doi: 10.3390/jcm10040787 PubMed DOI PMC

Farrell M, Fairfield H, Costa S, D’Amico A, Falank C, Brooks DJ, et al. . Sclerostin-neutralizing antibody treatment rescues negative effects of rosiglitazone on mouse bone parameters. J Bone Miner Res (2021) 36:158–69. doi: 10.1002/jbmr.4170 PubMed DOI PMC

Fairfield H, Falank C, Harris E, Demambro V, McDonald M, Pettitt JA, et al. . The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis. J Cell Physiol (2018) 233:1156–67. doi: 10.1002/jcp.25976 PubMed DOI PMC

Jackuliak P, Kuzma M, Payer J. Effect of antidiabetic treatment on bone. Physiol Res (2019) 68:S107–20. doi: 10.33549/physiolres.934297 PubMed DOI

Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 8:81–91. doi: 10.1038/nrendo.2011.146 PubMed DOI

Weivoda MM, Chew CK, Monroe DG, Farr JN, Atkinson EJ, Geske JR, et al. . Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nat Commun (2020) 11:87. doi: 10.1038/s41467-019-14003-6 PubMed DOI PMC

Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest (2019) 129:3214–23. doi: 10.1172/JCI125915 PubMed DOI PMC

Beekman KM, Akkerman EM, Streekstra GJ, Veldhuis-Vlug AG, Acherman Y, Gerdes VE, et al. . The effect of roux-en-y gastric bypass on bone marrow adipose tissue and bone mineral density in postmenopausal, nondiabetic women. Obes (Silver Spring) (2021) 29:1120–7. doi: 10.1002/oby.23171 PubMed DOI PMC

Limonard EJ, Veldhuis-Vlug AG, van Dussen L, Runge JH, Tanck MW, Endert E, et al. . Short-term effect of estrogen on human bone marrow fat. J Bone Miner Res (2015) 30:2058–66. doi: 10.1002/jbmr.2557 PubMed DOI

Syed FA, Oursler MJ, Hefferanm TE, Peterson JM, Riggs BL, Khosla S. Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Osteoporos Int (2008) 19:1323–30. doi: 10.1007/s00198-008-0574-6 PubMed DOI PMC

Schwartz AV, Sigurdsson S, Hue TF, Lang TF, Harris TB, Rosen CJ, et al. . Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults. J Clin Endocrinol Metab (2013) 98:2294–300. doi: 10.1210/jc.2012-3949 PubMed DOI PMC

Baum T, Yap SP, Karampinos DC, Nardo L, Kuo D, Burghardt AJ, et al. . Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus? J Magn Reson Imaging (2012) 35:117–24. doi: 10.1002/jmri.22757 PubMed DOI PMC

Duque G, Li W, Adams M, Xu S, Phipps R. Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporos Int (2011) 22:1547–53. doi: 10.1007/s00198-010-1353-8 PubMed DOI

Elbaz A, Rivas D, Duque G. Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Biogerontology (2009) 10:747–55. doi: 10.1007/s10522-009-9221-7 PubMed DOI

Martin RB, Chow BD, Lucas PA. Bone marrow fat content in relation to bone remodeling and serum chemistry in intact and ovariectomized dogs. Calcif Tissue Int (1990) 46:189–94. doi: 10.1007/BF02555043 PubMed DOI

Edelstein SL, Barrett-Connor E. Relation between body size and bone mineral density in elderly men and women. Am J Epidemiol (1993) 138:160–9. doi: 10.1093/oxfordjournals.aje.a116842 PubMed DOI

Jankowska EA, Rogucka E, Medras M. Are general obesity and visceral adiposity in men linked to reduced bone mineral content resulting from normal ageing? A population-based study. Andrologia (2001) 33:384–9. doi: 10.1046/j.1439-0272.2001.00469.x PubMed DOI

Yamaguchi T, Kanazawa I, Yamamoto M, Kurioka S, Yamauchi M, Yano S, et al. . Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Bone (2009) 45:174–9. doi: 10.1016/j.bone.2009.05.003 PubMed DOI

Greco EA, Fornari R, Rossi F, Santiemma V, Prossomariti G, Annoscia C, et al. . Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index. Int J Clin Pract (2010) 64:817–20. doi: 10.1111/j.1742-1241.2009.02301.x PubMed DOI

Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, et al. . Determinants of total body and regional bone mineral density in normal postmenopausal women–a key role for fat mass. J Clin Endocrinol Metab (1992) 75:45–51. doi: 10.1210/jcem.75.1.1619030 PubMed DOI

Slemenda CW, Hui SL, Longcope C, Johnston CC, Jr. Cigarette smoking, obesity, and bone mass. J Bone Miner Res (1989) 4:737–41. doi: 10.1002/jbmr.5650040513 PubMed DOI

Goulding A, Taylor RW. Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int (1998) 63:456–8. doi: 10.1007/s002239900557 PubMed DOI

Ricci TA, Chowdhury HA, Heymsfield SB, Stahl T, Pierson RN, Jr., Shapses SA. Calcium supplementation suppresses bone turnover during weight reduction in postmenopausal women. J Bone Miner Res (1998) 13:1045–50. doi: 10.1359/jbmr.1998.13.6.1045 PubMed DOI

Heidari B, Hosseini R, Javadian Y, Bijani A, Sateri MH, Nouroddini HG. Factors affecting bone mineral density in postmenopausal women. Arch Osteoporos (2015) 10:15. doi: 10.1007/s11657-015-0217-4 PubMed DOI

El Maghraoui A, Sadni S, El Maataoui A, Majjad A, Rezqi A, Ouzzif Z, et al. . Influence of obesity on vertebral fracture prevalence and vitamin D status in postmenopausal women. Nutr Metab (Lond) (2015) 12:44. doi: 10.1186/s12986-015-0041-2 PubMed DOI PMC

Andreoli A, Bazzocchi A, Celi M, Lauro D, Sorge R, Tarantino U, et al. . Relationship between body composition, body mass index and bone mineral density in a large population of normal, osteopenic and osteoporotic women. Radiol Med (2011) 116:1115–23. doi: 10.1007/s11547-011-0689-2 PubMed DOI

Karimifar M, Pasha MA, Salari A, Zamani A, Salesi M, Motaghi P. Evaluation of bone loss in diabetic postmenopausal women. J Res Med Sci (2012) 17:1033–8. PubMed PMC

Yanik B, Ayrim A, Ozol D, Koktener A, Gokmen D. Influence of obesity on bone mineral density in postmenopausal asthma patients undergoing treatment with inhaled corticosteroids. Clinics (Sao Paulo) (2009) 64:313–8. doi: 10.1590/s1807-59322009000400008 PubMed DOI PMC

Compston JE, Watts NB, Chapurlat R, Cooper C, Boonen S, Greenspan S, et al. . Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 124:1043–50. doi: 10.1016/j.amjmed.2011.06.013 PubMed DOI PMC

KIAA1199 (CEMIP) regulates adipogenesis and whole-body energy metabolism